(19)
(11) EP 1 569 634 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
29.08.2007 Bulletin 2007/35

(45) Mention of the grant of the patent:
16.05.2007 Bulletin 2007/20

(21) Application number: 03780062.0

(22) Date of filing: 26.11.2003
(51) International Patent Classification (IPC): 
A61K 31/192(2006.01)
A61K 31/195(2006.01)
A61K 31/155(2006.01)
 A61K 31/216(2006.01)
A61P 3/00(2006.01)
(86) International application number:
PCT/EP2003/013302
(87) International publication number:
WO 2004/047831 (10.06.2004 Gazette 2004/24)

(54)

USE OF A PPAR-ALPHA AGONIST AND METFORMIN FOR THE TREATMENT OF OBESITY

ZUSAMMENSETZUNG VON EINEM PPAR-ALPHA AGONISTEN UND METFORMIN ZUR BEHANDLUNG VON OBESITAS

UTILISATION D'UN AGONISTE PPAR-ALPHA ET METFORMINE POUR LE TRAITEMENT DE L'OBESITÉ

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: 28.11.2002 EP 02292940

(43) Date of publication of application:
07.09.2005 Bulletin 2005/36

(73) Proprietor: Fournier Laboratories Ireland Limited
Carrigtwohill, Co. Cork (IE)

(72) Inventors:
  • JUNIEN, Jean-Louis
    F-92310 SEVRES (FR)
  • EDGAR, Alan
    F-21490 SAINT-JULIEN (FR)
  • CHAPUT, Evelyne
    F-68510 SIERENTZ (FR)

(74) Representative: Hart Davis, Jason et al
Cabinet Beau de Loménie, 158, rue de l'Université
75007 Paris
75007 Paris (FR)


(56) References cited: : 
WO-A-98/05331
DE-A- 2 357 875
FR-A- 2 796 940
 WO-A-99/40904
FR-A- 2 275 199
   
  • DE SILVA S.R. ET AL: "Metformin and clofibrate in maturity onset diabetes mellitus: Advantages of combined treatment." DIABETE ET METABOLISME, 5/3 (223-229). CODEN: DIMEDU, 1979, XP008014771
  • CHEMICAL ABSTRACTS, vol. 133, no. 15, 9 October 2000 (2000-10-09), Columbus, Ohio, US; abstract no.: 202853, HUO, JIAXIN ET AL: "Effect of metformin on the lipid metabolism in patients with hyperlipidemia complicated with insulin resistance" XP002237098 & GUANGXI YIKE DAXUE XUEBAO, 16(6), 761-763, 1999,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).